Structure Therapeutics Inc. American Depositary Shares Net Assets
Structure Therapeutics Inc. American Depositary Shares net assets. Based on the latest financial reports, Structure Therapeutics Inc. American Depositary Shares (GPCR) has net assets worth $1.35 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.43 Billion) and total liabilities ($71.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Structure Therapeutics Inc. American Dep to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.35 Billion |
| % of Total Assets | 95.02% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.8 |
Net Assets of Structure Therapeutics Inc. American Depositary Shares (2020–2025)
Net assets of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025. This chart illustrates how Structure Therapeutics Inc. American Depositary Shares's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Structure Therapeutics Inc. American Dep to measure how much of total assets are equity-financed.
Annual Net Assets for Structure Therapeutics Inc. American Depositary Shares (2020–2025)
The table below shows the annual net assets of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025. For live market cap and overall valuation, see Structure Therapeutics Inc. American Dep market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.52 Billion | +75.34% |
| 2024-12-31 | $864.84 Million | +90.93% |
| 2023-12-31 | $452.97 Million | +493.40% |
| 2022-12-31 | $-115.14 Million | -77.86% |
| 2021-12-31 | $-64.73 Million | -188.11% |
| 2020-12-31 | $-22.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Structure Therapeutics Inc. American Depositary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44735400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Structure Therapeutics Inc. American Depositary Shares Net Assets Breakdown (December 2025)
Structure Therapeutics Inc. American Depositary Shares net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $21.00K | 0.00% |
| Other Comprehensive Income | $1.05 Million | 0.07% |
| Other Components | $1.99 Billion | 130.94% |
| Total Equity | $1.52 Billion | 100.00% |
Structure Therapeutics Inc. American Depositary Shares Competitors by Market Cap
The table below lists competitors of Structure Therapeutics Inc. American Depositary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nanobiotix
NASDAQ:NBTX
|
$1.45 Billion |
|
Global Ship Lease Inc
NYSE:GSL
|
$1.45 Billion |
|
YGSOFT Inc
SHE:002063
|
$1.45 Billion |
|
Guangdong Goworld Co Ltd
SHE:000823
|
$1.45 Billion |
|
TGS ASA SP.ADR/1
F:TGC0
|
$1.45 Billion |
|
Suning Commerce Group Co Ltd
SHE:002024
|
$1.45 Billion |
|
Shenzhen Colibri Technologies Co Ltd
SHE:002957
|
$1.45 Billion |
|
Quantum Computing Inc
NASDAQ:QUBT
|
$1.45 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Structure Therapeutics Inc. American Depositary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 864,843,000 to 1,516,377,000, a change of 651,534,000 (75.3%).
- Net loss of 141,202,000 reduced equity.
- New share issuances of 665,708,000 increased equity.
- Other comprehensive income increased equity by 140,000.
- Other factors increased equity by 126,888,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-141.20 Million | -9.31% |
| Share Issuances | $665.71 Million | +43.9% |
| Other Comprehensive Income | $140.00K | +0.01% |
| Other Changes | $126.89 Million | +8.37% |
| Total Change | $- | 75.34% |
Book Value vs Market Value Analysis
This analysis compares Structure Therapeutics Inc. American Depositary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.79x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.61 | $20.35 | x |
| 2021-12-31 | $-1.77 | $20.35 | x |
| 2022-12-31 | $-3.15 | $20.35 | x |
| 2023-12-31 | $12.33 | $20.35 | x |
| 2024-12-31 | $16.43 | $20.35 | x |
| 2025-12-31 | $25.62 | $20.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Structure Therapeutics Inc. American Depositary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-9.31%) is below the historical average (-7.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $2.23 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-33.53 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-39.81 Million |
| 2023 | -19.79% | 0.00% | 0.00x | 1.06x | $-134.92 Million |
| 2024 | -14.17% | 0.00% | 0.00x | 1.04x | $-209.01 Million |
| 2025 | -9.31% | 0.00% | 0.00x | 1.04x | $-292.84 Million |
Industry Comparison
This section compares Structure Therapeutics Inc. American Depositary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.35 Billion | 0.00% | 0.05x | $1.45 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more